Czech cancer patients among the least likely in Europe to be prescribed the latest medicines, says Swedish study

A new study by the Karolinska Institute of Sweden has found that cancer patients in the Czech Republic are among the least likely in Europe to be treated with the latest medicines. The report, which is due to be presented to the European Parliament this week, also singled out Hungary, Norway, Poland and the United Kingdom in this regard. The Stockholm-based institute said shortages in new cancer drugs are generally caused by tight financial controls in countries like the Czech Republic and by delays in approving medicines.